Ge Long Hui A P P·2025-09-26 09:25Core Viewpoint - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Clone, with the proceeds aimed at further investment in innovative drug business [1] Group 1: Transaction Details - Fosun Pharma's subsidiary, Fosun Pharma Industry, intends to contribute RMB 54.6 million as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance [1] - The subsidiary expects to hold a 9.98% share of the fund's assets after full fundraising [1] - The subsidiary plans to transfer its 100% equity in Shanghai Clone and related debts for no more than RMB 1.256 billion to the special fund or its controlled entities [1] Group 2: Operational Impact - Following the transfer, the group will no longer hold direct equity in Shanghai Clone but will continue to lease part of the property as an operational site [1] - The transaction is expected to have no significant impact on the group's daily operations [1] Group 3: Use of Proceeds - Proceeds from the transfer will be utilized for ongoing investments in the group's innovative drug business [1]